Amylyx Pharmaceuticals
AMLX
AMLX
133 hedge funds and large institutions have $1.79B invested in Amylyx Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 49 increasing their positions, 32 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
9.64% more ownership
Funds ownership: 63.67% → 73.31% (+9.6%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
30% less call options, than puts
Call options by funds: $25M | Put options by funds: $35.5M
Holders
133
Holding in Top 10
5
Calls
$25M
Puts
$35.5M
Top Buyers
| 1 | +$99.5M | |
| 2 | +$61.4M | |
| 3 | +$48.8M | |
| 4 |
D.E. Shaw & Co
New York
|
+$45.1M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$41.4M |
Top Sellers
| 1 | -$42M | |
| 2 | -$28.8M | |
| 3 | -$27.7M | |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$18.9M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$14M |